Glial modulators: A novel pharmacological approach to altering the behavioral effects of abused substances

Expert Opinion on Investigational Drugs

Volumn 21, Issue 2, 2012, Pages 169-178

  Cooper, Ziva D ^a   Jones, Jermaine D ^a   Comer, Sandra D ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Abuse; Alcohol; Dependence; Glia; Opioids; Stimulants

Indexed keywords

ALCOHOL; CENTRAL STIMULANT AGENT; IBUDILAST; MINOCYCLINE; MORPHINE; OPIATE; PROPENTOFYLLINE;

ALCOHOLISM; CELL ACTIVITY; CELL FUNCTION; DRUG TOLERANCE; GLIA CELL; HUMAN; NONHUMAN; OPIATE ADDICTION; PLACE PREFERENCE; REVIEW; SUBSTANCE ABUSE;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ADDICTIVE; CENTRAL NERVOUS SYSTEM STIMULANTS; ETHANOL; HUMANS; NEUROGLIA; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84863395562     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.651123     Document Type: Review

References (77)

1. Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol Aging 2008;29:1754-62
2. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-18 (Pubitemid 26349059)
3. Nakajima K, Kohsaka S. Functional roles of microglia in the brain. Neurosci Res 1993;17:187-203 (Pubitemid 23266177)
4. Stoll G, Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 1999;58:233-47 (Pubitemid 29193056)
5. Verkhratsky A, Kettenman H. Calcium signaling in glial cells. Trends Neurosci 1996;19:346-52
6. Okimura Y, Tanno H, Fukuda K, et al. Reactive astrocytes in acute stage after experimental brain injury: relationship to extravasated plasma protein and expression of heat shock protein. J Neurotrauma 1996;13:385-93 (Pubitemid 26405761)
7. Svendsen CN. Neurobiology: The amazing astrocyte. Nature 2002;417:29-32 (Pubitemid 34498802)
8. Ullian EM, Sapperstein SK, Christopherson KS, Barres BA. Control of synapse number by glia. Science 2001;291:657-61 (Pubitemid 32150425)
9. Nakajima K, Kohsaka S. Microglia: activation and their significance in the central nervous system. J Biochem 2001;130:169-75 (Pubitemid 32785862)
10. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings. Rockville, MD, 2008a (NSDUH Series H-34, DHHS Publication No. SMA 08-4343)
11. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD, 2008b (DAWN Series D-30, DHHS Publication No. SMA 08-4339)
12. Cooper ZD, Truong YN, Shi YG, Woods JH. Morphine deprivation increases self-administration of the fastand short-acting mu-opioid receptor agonist remifentanil in the rat. J Pharmacol Exp Ther 2008;326:920-9
13. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006;104:570-87
14. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counterregulators of opioid analgesia. Trends Neurosci 2005;28:661-9 (Pubitemid 41654390)
15. Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 1985;8:203-14 (Pubitemid 15025252)
16. Beitner-Johnson D, Guitart X, Nestler EJ. Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area. J Neurochem 1993;61:1766-73 (Pubitemid 23317200)
17. Garrido E, Perez-Garcia C, Alguacil LF, Diez-Fernandez C. The alpha2-adrenoceptor antagonist yohimbine reduces glial fibrillary acidic protein upregulation induced by chronic morphine administration. Neurosci Lett 2005;383:141-4 (Pubitemid 40779971)
18. Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001;39:281-6 (Pubitemid 32186379)
19. Rasmussen K, Beitner-Johnson DB, Krystal JH, et al. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J Neurosci 1990;10:2308-17
20. Marie-Claire C, Courtin C, Roques BP, Noble F. Cytoskeletal genes regulation by chronic morphine treatment in rat striatum. Neuropsychopharmacology 2004;29:2208-15 (Pubitemid 39578911)
21. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 1992;654:171-91
22. Narita M, Miyatake M, Narita M, et al. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006;31:2476-88 (Pubitemid 44607065)
23. American Academy of Pain Medicine (APM) & American Pain Society (APS). The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997;13:6-8
24. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002;100:213-17 (Pubitemid 35449233)
25. Cannon JG. Inflammatory Cytokines in Nonpathological States. News Physiol Sci 2000;15:298-303
26. Walter MR. Structural biology of cytokines, their receptors, and signaling complexes: implications for the immune and neuroendocrine circuit. Chem Immunol 1997;69:76-98 (Pubitemid 27466558)
27. Johnston IN, Milligan ED, Wieseler-Frank J, et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004;24:7353-65 (Pubitemid 39100704)
28. Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol 1998;83:63-9 (Pubitemid 28280952)
29. Stefano GB. Autoimmunovascular regulation: morphine and anandamide and ancodamide stimulated nitric oxide release. J Neuroimmunol 1998;83:70-6 (Pubitemid 28280953)
30. Takayama N, Ueda H. Morphine-induced chemotaxis and brain-derived neurotrophic factor expression in microglia. J Neurosci 2005;25:430-5 (Pubitemid 40105613)
31. Hutchinson MR, Coats BD, Lewis SS, et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008;22:1178-89
32. Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002;22:9980-9 (Pubitemid 35332883)
33. Raghavendra V, Tanga FY, DeLeo JA. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 2004;29:327-34 (Pubitemid 38175151)
34. Hutchinson MR, Lewis SS, Coats BD, et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 2009;23:240-50
35. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007;16:935-50 (Pubitemid 47078775)
36. Ledeboer A, Sloane EM, Milligan ED, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005;115:71-83
37. Mika J, Osikowicz M, Makuch W, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007;560:142-9 (Pubitemid 46341303)
38. Raghavendra V, Tanga F, Rutkowski MD, DeLeo JA. Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain 2003;104:655-64 (Pubitemid 37289065)
39. Dorazil-Dudzik M, Mika J, Schafer MK, et al. The effects of local pentoxifylline and propentofylline treatment on formalin-induced pain and tumor necrosis factor-alpha messenger RNA levels in the inflamed tissue of the rat paw. Anesth Analg 2004;98:1566-73 (Pubitemid 38668896)
40. Tawfik VL, Nutile-McMenemy N, Lacroix-Fralish ML, Deleo JA. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun 2007;21:238-46 (Pubitemid 46038912)
41. Sweitzer S, De Leo J. Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain. Methylxanthines, Handbook of Experimental Pharmacology 200. Springer-Verlag; Berlin: 2011
42. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll like receptor 4 and MD-2 effects. Brain Behav Immun 2010;24:83-95
43. Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 2008;60:297-307
44. Shavit Y, Wolf G, Goshen I, et al. Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain 2005;115:50-9
45. Liu W, Wang CH, Cui Y, et al. Inhibition of neuronal nitric oxide synthase antagonizes morphine antinociceptive tolerance by decreasing activation of p38 MAPK in the spinal microglia. Neurosci Lett 2006;410:174-7 (Pubitemid 44750337)
46. Bland ST, Hutchinson MR, Maier SF, et al. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain Behav Immun 2009;23:492-7
47. Hutchinson MR, Bland ST, Johnson KW, et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence and reward. ScientificWorldJournal 2007;7:98-111 (Pubitemid 350292608)
48. Thomas DM, Dowgiert J, Geddes TJ, et al. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 2004;367:349-54 (Pubitemid 39178611)
49. Armstrong V, Reichel CM, Doti JF, et al. Repeated amphetamine treatment causes a persistent elevation of glial fibrillary acidic protein in the caudate-putamen. Eur J Pharmacol 2004;488:111-15 (Pubitemid 38388530)
50. Hou YJ, Yu AC, Garcia JM, et al. Astrogliosis in culture. IV. Effects of basic fibroblast growth factor. J Neurosci Res 1995;40:359-70
51. Flores C, Rodaros D, Stewart J. Long-lasting induction of astrocytic basic fibroblast growth factor by repeated injections of amphetamine: blockade by concurrent treatment with a glutamate antagonist. J Neurosci 1998;18:9547-55 (Pubitemid 28512483)
52. Flores C, Samaha AN, Stewart J. Requirement of endogenous basic fibroblast growth factor for sensitization to amphetamine. J Neurosci 2000;20:RC55
53. Fantegrossi WE, Ciullo JR, Wakabayashi KT, et al. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neurosci 2008;151:533-43
54. Pubill D, Canudas AM, Pallas M, et al. Different glial response to methamphetamine-and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 2003;367:490-9 (Pubitemid 36718300)
55. Thomas DM, Walker PD, Benjamins JA, et al. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 2004;311:1-7 (Pubitemid 39287777)
56. Zhang L, Kitaichi K, Fujimoto Y, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1381-93 (Pubitemid 44634942)
57. Park CH, Carboni E, Wood PL, Gee KW. Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia 1996;16:65-70 (Pubitemid 26350512)
58. Kato H, Kogure K, Liu XH, et al. Immunohistochemical localization of the low molecular weight stress protein HSP27 following focal cerebral ischemia in the rat. Brain Res 1995;679:1-7
59. Sekine Y, Ouchi Y, Sugihara G, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 2008;28:5756-61
60. Banati RB. Visualising microglial activation in vivo. Glia 2002;40:206-17 (Pubitemid 35337378)
61. Hashimoto K, Tsukada H, Nishiyama S, et al. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. Biol Psychiatry 2007;61:577-81 (Pubitemid 46328849)
62. Mizoguchi H, Yamada K, Nabeshima T. Neuropsychotoxicity of abused drugs: involvement of matrix metalloproteinase-2 and-9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents. J Pharmacol Sci 2008;106:9-14 (Pubitemid 351159063)
63. Beardsley PM, Shelton KL, Hendrick E, Johnson KW. The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime-and stress-induced methamphetamine relapse. Eur J Pharmacol 2010;637:102-8
64. Sofuoglu M, Mooney M, Kosten T, et al. Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacology (Berl) 2011;213:61-8
65. Fattore L, Puddu MC, Picciau S, et al. Astroglial in vivo response to cocaine in mouse dentate gyrus: a quantitative and qualitative analysis by confocal microscopy. Neurosci 2002;110:1-6 (Pubitemid 34214754)
66. Bowers MS, Kalivas PW. Forebrain astroglial plasticity is induced following withdrawal from repeated cocaine administration. Eur J Neurosci 2003;17:1273-8 (Pubitemid 36459781)
67. Chen H, Uz T, Manev H. Minocycline affects cocaine sensitization in mice. Neurosci Lett 2009;452:258-61
68. Ciraulo DA, Sarid-Segal O, Knapp CM, et al. Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. Addiction 2005;100(Suppl 1):12-22 (Pubitemid 40363421)
69. Grant BF, Stinson FS, Dawson DA, et al. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:361-8 (Pubitemid 38451545)
70. Crews FT, Nixon K. Mechanisms of neurodegeneration and regeneration in alcoholism. Alcohol 2009;44:115-27
71. Obernier JA, White AM, Swartzwelder HS, Crews FT. Cognitive deficits and CNS damage after a 4-day binge ethanol exposure in rats. Pharmacol Biochem Behav 2002;72:521-32 (Pubitemid 34450852)
72. Ward RJ, Colivicchi MA, Allen R, et al. Neuro-inflammation induced in the hippocampus of 'binge drinking' rats may be mediated by elevated extracellular glutamate content. J Neurochem 2009;111:1119-28
73. He J, Crews FT. Increased MCP-1 and microglia in various regions of the human alcoholic brain. Exp Neurol 2008;210:349-58
74. Agrawal RG, Hewetson A, George CM, et al. Minocycline reduces ethanol drinking. Brain Behav Immun 2011;25:S165-9
75. Stopponi S, Somaini L, Cippitelli A, et al. Activation of the nuclear PPAR receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 2011;69:642-9
76. Hutchinson MR, Shavit Y, Grace PM, et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 2011;63:772-810
77. Frank MG, Watkins LR, Maier SF. Stress-and glucocorticoid-induced priming of neuroinflammatory responses: potential mechanisms of stress-induced vulnerability of drugs of abuse. Brain Behav Immun 2011;25:S21-8